HRP20191143T1 - Farmaceutski pripravci koji sadrže korteksolon-17-alfa-propionat - Google Patents
Farmaceutski pripravci koji sadrže korteksolon-17-alfa-propionat Download PDFInfo
- Publication number
- HRP20191143T1 HRP20191143T1 HRP20191143TT HRP20191143T HRP20191143T1 HR P20191143 T1 HRP20191143 T1 HR P20191143T1 HR P20191143T T HRP20191143T T HR P20191143TT HR P20191143 T HRP20191143 T HR P20191143T HR P20191143 T1 HRP20191143 T1 HR P20191143T1
- Authority
- HR
- Croatia
- Prior art keywords
- spectrum
- crystalline form
- pharmaceutical preparation
- propionate
- cortexolone
- Prior art date
Links
- GPNHMOZDMYNCPO-PDUMRIMRSA-N clascoterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CC)[C@@]1(C)CC2 GPNHMOZDMYNCPO-PDUMRIMRSA-N 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 238000001228 spectrum Methods 0.000 claims 3
- 238000002329 infrared spectrum Methods 0.000 claims 2
- 239000006072 paste Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000006155 precocious puberty Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000009329 sexual behaviour Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/005—Degradation of the lateral chains at position 17
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Claims (5)
1. Farmaceutski pripravak koji sadrži najmanje jedan kristalni oblik korteksolon-17α-propionata u vezi sa najmanje jednim fiziološki prihvatljivim ekscipijensom, gdje navedeni najmanje jedan kristalni oblik korteksolon-17α-propionata je odabran od: kristalnog oblika I okarakterizirano pomoću DRX kao što je prikazano na slici 1 i DSC kao što je prikazano na slici 2 i IR spektra kao što je prikazano na slici 3; kristalnog oblika III okarakterizirano pomoću DRX spektra kao što je prikazano na slici 7 ili 10 ili 13 i DSC spektra kao što je prikazano na slici 8 ili 11 ili 14 i IR spektra kao što je prikazano na slici 9 ili 12 ili 15; hidratnog kristalnog oblika IV okarakterizirano pomoću DRX spektra kao što je prikazano na slici 28.
2. Farmaceutski pripravak prema patentnom zahtjevu 1 u čvrstom, polu-čvrstom obliku ili obliku paste.
3. Farmaceutski pripravak prema patentnom zahtjevu 2 u obliku tablete, kapsule, praška, pilule, suspenzije, emulzije, kreme, gela, masti, losiona, disperzije ili paste.
4. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3 za primjenu u liječenju patologija koje utječu na urogenitalni sistem, endokrini sistem, kožu i/ili kožne tvorevine.
5. Farmaceutski pripravak za primjenu prema patentnom zahtjevu 4 za liječenje akni, seboreičnog dermatitisa, androgenetske alopecije, hirzutizma, benigne hiperplazije prostate, oblika raka prostate, sindroma policističnih jajnika, sindroma preranog puberteta i kontrole agresivnog ili aberantnih seksualnih ponašanja.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001616A ITMI20071616A1 (it) | 2007-08-03 | 2007-08-03 | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| EP15175112.0A EP2966175B1 (en) | 2007-08-03 | 2008-07-24 | Pharmaceutical compositions containing cortexolone-17-alpha-propionate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191143T1 true HRP20191143T1 (hr) | 2019-09-20 |
Family
ID=40278805
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140421AT HRP20140421T1 (hr) | 2007-08-03 | 2014-05-09 | ENZIMSKI POSTUPAK DOBIVANJA KORTERKSOLON-17alfa-PROPIONATA, U KRISTALNOM OBLIKU III |
| HRP20151174TT HRP20151174T1 (hr) | 2007-08-03 | 2015-11-03 | KORTEKSOLON-17α-PROPIONAT U HIDRATNOM KRISTALNOM OBLIKU IV |
| HRP20151298TT HRP20151298T1 (hr) | 2007-08-03 | 2015-11-30 | KORTEKSOLON-17α-PROPIONAT U KRISTALNOM OBLIKU I |
| HRP20191143TT HRP20191143T1 (hr) | 2007-08-03 | 2019-06-24 | Farmaceutski pripravci koji sadrže korteksolon-17-alfa-propionat |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140421AT HRP20140421T1 (hr) | 2007-08-03 | 2014-05-09 | ENZIMSKI POSTUPAK DOBIVANJA KORTERKSOLON-17alfa-PROPIONATA, U KRISTALNOM OBLIKU III |
| HRP20151174TT HRP20151174T1 (hr) | 2007-08-03 | 2015-11-03 | KORTEKSOLON-17α-PROPIONAT U HIDRATNOM KRISTALNOM OBLIKU IV |
| HRP20151298TT HRP20151298T1 (hr) | 2007-08-03 | 2015-11-30 | KORTEKSOLON-17α-PROPIONAT U KRISTALNOM OBLIKU I |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US8785427B2 (hr) |
| EP (5) | EP2966175B1 (hr) |
| JP (3) | JP5646992B2 (hr) |
| KR (1) | KR101495192B1 (hr) |
| CN (3) | CN101743316B (hr) |
| AR (3) | AR072235A1 (hr) |
| AU (1) | AU2008285784B2 (hr) |
| BR (1) | BRPI0814163A2 (hr) |
| CA (3) | CA2691445C (hr) |
| DK (4) | DK2503005T3 (hr) |
| ES (4) | ES2732326T3 (hr) |
| HR (4) | HRP20140421T1 (hr) |
| HU (3) | HUE026206T2 (hr) |
| IT (1) | ITMI20071616A1 (hr) |
| LT (1) | LT2966175T (hr) |
| MX (4) | MX363238B (hr) |
| NZ (3) | NZ600767A (hr) |
| PL (4) | PL2503005T3 (hr) |
| PT (4) | PT2503004E (hr) |
| RS (4) | RS54354B1 (hr) |
| RU (2) | RU2482190C2 (hr) |
| SI (4) | SI2173891T1 (hr) |
| TR (1) | TR201909129T4 (hr) |
| WO (1) | WO2009019138A2 (hr) |
| ZA (2) | ZA201000587B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| ITMI20132157A1 (it) | 2013-12-20 | 2015-06-21 | Cosmo Dermatos Srl | Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle. |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
| CN112028956A (zh) * | 2020-09-10 | 2020-12-04 | 那路新 | 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法 |
| FR3115284B1 (fr) | 2020-10-19 | 2023-12-08 | Ind Chimica Srl | Procédé de préparation de 21-(acétyloxy)-17-(1-oxopropoxy)-prégn-4-ène-3,20-dione |
| IT202100008429A1 (it) | 2021-04-06 | 2022-10-06 | Farmabios Spa | Processo per la preparazione di cortexolone 17α-propionato e sua nuova forma cristallina idrata |
| CN114410727B (zh) * | 2022-01-25 | 2023-09-19 | 山东诺明康药物研究院有限公司 | 一种克拉考特酮的制备方法 |
| CN115073546A (zh) * | 2022-06-01 | 2022-09-20 | 浙江神洲药业有限公司 | 一种新型雄激素受体抑制剂的制备方法 |
| CN115466301A (zh) * | 2022-08-29 | 2022-12-13 | 扬州奥锐特药业有限公司 | 一种甾体化合物，其晶型a及它们的制备方法和用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791771A (en) | 1954-07-29 | 1958-03-12 | Merck & Co Inc | Steroid compounds |
| US2985650A (en) | 1958-05-28 | 1961-05-23 | Syntex Sa | 6alpha-ammonio-derivatives of 11-keto cortical hormones |
| CH429716A (de) | 1961-06-24 | 1967-02-15 | Vismara Francesco Spa | Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden |
| NL6605515A (hr) | 1966-04-25 | 1967-10-26 | ||
| NL6605514A (hr) * | 1966-04-25 | 1967-10-26 | ||
| US3780177A (en) | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
| US3733318A (en) | 1972-03-23 | 1973-05-15 | Syntex Corp | 21-orthoesters of cortical steroids and methods of preparing same |
| JPS5910799B2 (ja) * | 1975-07-15 | 1984-03-12 | 大正製薬株式会社 | プレグナン系ステロイド １７−エステル類の製法 |
| GB2109817B (en) | 1981-11-18 | 1985-07-03 | Ibm | Electrodeposition of chromium |
| DE3243482A1 (de) | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
| DE3402330A1 (de) | 1984-01-20 | 1985-07-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4920216A (en) | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
| US5264428A (en) | 1990-02-16 | 1993-11-23 | Kanoldt Arzneimittel Gmbh | Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases |
| JPH08135789A (ja) | 1994-11-09 | 1996-05-31 | Komatsu Ltd | 車両の油圧式駆動装置の変速装置およびその変速制御方法 |
| DE19653730C2 (de) * | 1996-12-11 | 1999-06-24 | Schering Ag | Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern |
| CN1090180C (zh) | 1997-06-25 | 2002-09-04 | 帝人株式会社 | 维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂 |
| JP2004530703A (ja) | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
| ITMI20011762A1 (it) | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
| WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
| AU2003221160A1 (en) | 2002-03-27 | 2003-10-08 | Shionogi And Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| ES2273061T3 (es) | 2002-08-02 | 2007-05-01 | Schering Aktiengesellschaft | Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal. |
| EP1539183A4 (en) | 2002-08-28 | 2007-04-25 | Hollis Eden Pharmaceuticals | THERAPEUTIC TREATMENT METHODS |
| AR043444A1 (es) | 2003-03-05 | 2005-07-27 | Merck Frosst Canada Inc | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 |
| US20050008704A1 (en) | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| ITMI20051695A1 (it) * | 2005-09-14 | 2007-03-15 | Cosmo Spa | Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici |
| ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| ITMI20132157A1 (it) | 2013-12-20 | 2015-06-21 | Cosmo Dermatos Srl | Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle. |
| EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
-
2007
- 2007-08-03 IT IT001616A patent/ITMI20071616A1/it unknown
-
2008
- 2008-07-18 AR ARP080103135A patent/AR072235A1/es unknown
- 2008-07-24 ES ES15175112T patent/ES2732326T3/es active Active
- 2008-07-24 LT LTEP15175112.0T patent/LT2966175T/lt unknown
- 2008-07-24 HU HUE12173152A patent/HUE026206T2/hu unknown
- 2008-07-24 CA CA2691445A patent/CA2691445C/en not_active Expired - Fee Related
- 2008-07-24 SI SI200831199T patent/SI2173891T1/sl unknown
- 2008-07-24 RU RU2010107599/10A patent/RU2482190C2/ru active
- 2008-07-24 SI SI200831538T patent/SI2503005T1/sl unknown
- 2008-07-24 ES ES08775319.0T patent/ES2462946T3/es active Active
- 2008-07-24 PL PL12173228T patent/PL2503005T3/pl unknown
- 2008-07-24 PL PL12173152T patent/PL2503004T3/pl unknown
- 2008-07-24 HU HUE15175112 patent/HUE044237T2/hu unknown
- 2008-07-24 PT PT121731525T patent/PT2503004E/pt unknown
- 2008-07-24 ES ES12173152.5T patent/ES2551910T3/es active Active
- 2008-07-24 EP EP15175112.0A patent/EP2966175B1/en active Active
- 2008-07-24 PT PT15175112T patent/PT2966175T/pt unknown
- 2008-07-24 AU AU2008285784A patent/AU2008285784B2/en active Active
- 2008-07-24 CA CA2871039A patent/CA2871039C/en not_active Expired - Fee Related
- 2008-07-24 PL PL08775319T patent/PL2173891T3/pl unknown
- 2008-07-24 CA CA2871025A patent/CA2871025C/en not_active Expired - Fee Related
- 2008-07-24 SI SI200831528T patent/SI2503004T1/sl unknown
- 2008-07-24 TR TR2019/09129T patent/TR201909129T4/tr unknown
- 2008-07-24 ES ES12173228.3T patent/ES2554934T3/es active Active
- 2008-07-24 PT PT87753190T patent/PT2173891E/pt unknown
- 2008-07-24 MX MX2014009552A patent/MX363238B/es unknown
- 2008-07-24 DK DK12173228.3T patent/DK2503005T3/en active
- 2008-07-24 NZ NZ600767A patent/NZ600767A/xx unknown
- 2008-07-24 CN CN2008800245389A patent/CN101743316B/zh active Active
- 2008-07-24 EP EP19163462.5A patent/EP3521298A1/en active Pending
- 2008-07-24 CN CN201510158436.8A patent/CN104861023B/zh active Active
- 2008-07-24 PL PL15175112T patent/PL2966175T3/pl unknown
- 2008-07-24 CN CN201310339201.XA patent/CN103450304B/zh active Active
- 2008-07-24 EP EP08775319.0A patent/EP2173891B1/en active Active
- 2008-07-24 RS RS20150691A patent/RS54354B1/en unknown
- 2008-07-24 PT PT121732283T patent/PT2503005E/pt unknown
- 2008-07-24 MX MX2014009553A patent/MX363701B/es unknown
- 2008-07-24 EP EP12173152.5A patent/EP2503004B1/en active Active
- 2008-07-24 EP EP12173228.3A patent/EP2503005B1/en active Active
- 2008-07-24 SI SI200832066T patent/SI2966175T1/sl unknown
- 2008-07-24 HU HUE12173228A patent/HUE026507T2/hu unknown
- 2008-07-24 RS RS20190782A patent/RS58950B1/sr unknown
- 2008-07-24 US US12/671,932 patent/US8785427B2/en active Active
- 2008-07-24 DK DK12173152.5T patent/DK2503004T3/en active
- 2008-07-24 WO PCT/EP2008/059702 patent/WO2009019138A2/en active Application Filing
- 2008-07-24 DK DK15175112.0T patent/DK2966175T3/da active
- 2008-07-24 JP JP2010518628A patent/JP5646992B2/ja active Active
- 2008-07-24 KR KR1020107003182A patent/KR101495192B1/ko active IP Right Grant
- 2008-07-24 RS RS20150723A patent/RS54361B1/en unknown
- 2008-07-24 BR BRPI0814163-0A2A patent/BRPI0814163A2/pt not_active Application Discontinuation
- 2008-07-24 NZ NZ61595308A patent/NZ615953A/en unknown
- 2008-07-24 MX MX2010001256A patent/MX2010001256A/es active IP Right Grant
- 2008-07-24 NZ NZ599437A patent/NZ599437A/xx unknown
- 2008-07-24 DK DK08775319.0T patent/DK2173891T3/da active
- 2008-07-24 RS RS20140233A patent/RS53310B/en unknown
-
2010
- 2010-01-26 ZA ZA2010/00587A patent/ZA201000587B/en unknown
- 2010-01-29 MX MX2019003639A patent/MX2019003639A/es active IP Right Grant
-
2011
- 2011-01-05 ZA ZA2011/00133A patent/ZA201100133B/en unknown
-
2012
- 2012-04-09 RU RU2012113839/10A patent/RU2599452C2/ru active
-
2013
- 2013-05-02 JP JP2013097009A patent/JP6108944B2/ja active Active
- 2013-11-07 US US14/073,928 patent/US9433628B2/en active Active
-
2014
- 2014-05-09 HR HRP20140421AT patent/HRP20140421T1/hr unknown
-
2015
- 2015-09-18 JP JP2015185882A patent/JP6174645B2/ja active Active
- 2015-10-19 US US14/886,774 patent/US9486458B2/en active Active
- 2015-11-03 HR HRP20151174TT patent/HRP20151174T1/hr unknown
- 2015-11-30 HR HRP20151298TT patent/HRP20151298T1/hr unknown
-
2016
- 2016-07-15 US US15/211,094 patent/US10159682B2/en active Active
- 2016-07-15 US US15/211,087 patent/US10166245B2/en active Active
-
2018
- 2018-04-03 AR ARP180100811A patent/AR111202A2/es unknown
- 2018-04-03 AR ARP180100810A patent/AR111351A2/es unknown
- 2018-11-19 US US16/195,083 patent/US10716796B2/en active Active
-
2019
- 2019-06-24 HR HRP20191143TT patent/HRP20191143T1/hr unknown
- 2019-11-18 US US16/686,738 patent/US11207332B2/en active Active
-
2021
- 2021-11-18 US US17/455,538 patent/US11938141B2/en active Active
-
2022
- 2022-11-18 US US18/057,031 patent/US20230104965A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191143T1 (hr) | Farmaceutski pripravci koji sadrže korteksolon-17-alfa-propionat | |
| TNSN08366A1 (en) | Novel compositions for hair disorders and process of preparation thereof | |
| AU2008281460A8 (en) | Continuous spray sunscreen compositions | |
| NZ611467A (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
| WO2009072027A3 (en) | Shampoo containing a gel network | |
| JPH10503197A (ja) | 汗関連症状の治療法 | |
| NZ594024A (en) | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient | |
| WO2008062429A3 (en) | Particles for delivery of active ingredients, process of making and compositions thereof | |
| WO2008081831A1 (ja) | 皮膚外用剤および美白剤 | |
| UA103340C2 (ru) | Терапевтическое, диетологическое или косметическое применение соединений со специфическим антиапоптозным дейсвием на каспазу-3 и композиция, которая содержит эти соединения | |
| CN104706551A (zh) | 一种含藤茶提取物的洗面奶 | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| TW200715995A (en) | Coenzyme q10-containing water-soluble composition and process for production thereof | |
| JP6860558B2 (ja) | ソヤサポニンを含有する発毛および／または育毛促進用組成物 | |
| JP2015124188A (ja) | 皮脂合成抑制剤 | |
| MX2010002649A (es) | Composicion cosmetica para administracion topica en forma de spray. | |
| BR112019001799B1 (pt) | Composição para cuidados pessoais, processo para preparar uma composição e uso de uma composição | |
| JP2012006895A (ja) | メラニン産生促進剤 | |
| CN103521383A (zh) | 一种新型花洒结构 | |
| Xin et al. | Effects of irrigation model and nitrogen fertilization on rice evapotranspiration and yield | |
| CN105232353A (zh) | 一种清凉型防晒霜或润肤霜及其制备方法 | |
| WO2011149206A3 (en) | Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same | |
| CN103110557B (zh) | 具有清爽止汗作用的洗浴搓茶及其制备方法 | |
| 도지윤 et al. | Synthesis of retinol derivatives for anti-aging cosmetic ingredients | |
| CN106265186A (zh) | 一种薄荷精油洗手液 |